© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jan 24, 2015, the consensus forecast amongst 47 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for AstraZeneca PLC. View Full Financials
In 2013, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 28 analysts covering the company expect dividends of 2.79 USD for the upcoming fiscal year, a decrease of 0.50%. View Full Financials
|Div growth (TTM)||0.00%|
On Nov 06, 2014, AstraZeneca plc reported 3rd quarter 2014 earnings of 1.05 per share. This result was in line with the consensus of the 13 analysts following the company and under-performed last year's 3rd quarter results by 13.93%. View Full Interim Financials
|Average growth rate||-3.04%|
AstraZeneca plc reported annual 2013 earnings of 5.05 per share on Feb 06, 2014. View Full Annual Financials
|Average growth rate||-4.07%|
AstraZeneca PLC had 3rd quarter 2014 revenues of 6.54bn. This bettered the 6.41bn consensus of the 13 analysts covering the company. This was 1.36% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+1.30%|
AstraZeneca PLC had revenues for the full year 2013 of 25.71bn. This was 8.09% below the prior year's results. View Full Annual Financials
|Average growth rate||-5.61%|